{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:33:37Z","timestamp":1777318417356,"version":"3.51.4"},"reference-count":62,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Arising from the immune system and located primarily in lymphoid organs, Hodgkin lymphoma (HL) is one of the most common cancers in young adults. Risk-adapted first-line treatment usually consisting of multi-agent chemotherapy and often incorporating consolidative radiation therapy aims at long-term cure. Although this is achieved in the vast majority of patients, therapy-related side effects such as organ damage, second cancers, and fatigue constitute considerable sequelae and outweigh HL as the cause of mortality after successful first-line treatment. In addition, intensive conventional therapy is seldom feasible in elderly or frail patients, diminishing chances of cure in this growing population of patients. The rapidly growing understanding of HL biology, innovative clinical trials, and the incorporation of novel drugs might help to overcome these obstacles in the management of HL. In this review, recent advances in the understanding and care of HL will be summarized with a focus on ongoing and future strategies which might help move things forward.<\/ns4:p>","DOI":"10.12688\/f1000research.16077.1","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T15:00:18Z","timestamp":1542121218000},"page":"1786","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Moving things forward in Hodgkin lymphoma"],"prefix":"10.12688","volume":"7","author":[{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-0981","authenticated-orcid":false,"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"ref-1","first-page":"112-115","article-title":"Krebs in Deutschland, ICD-10 C81 Morbus Hodgkin","year":"2013"},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"5-29","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015.","volume":"65","author":"R Siegel","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"155-64","DOI":"10.1053\/j.seminhematol.2016.05.003","article-title":"Prognostic factors in Hodgkin lymphoma.","volume":"53","author":"P Br\u00f6ckelmann","year":"2016","journal-title":"Semin Hematol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1418-27","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.","volume":"385","author":"K Behringer","year":"2015","journal-title":"Lancet."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"907-13","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.","volume":"30","author":"B von Tresckow","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"2790-802","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.","volume":"390","author":"P Borchmann","year":"2018","journal-title":"Lancet."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1999-2007","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.","volume":"35","author":"S Sasse","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"5074-80","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.","volume":"28","author":"A Josting","year":"2010","journal-title":"J Clin Oncol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1283-94","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.","volume":"17","author":"A Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"2183-9","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.","volume":"30","author":"A Younes","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2125-32","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma.","volume":"35","author":"R Chen","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"3373-9","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects.","volume":"124","author":"A Ng","year":"2014","journal-title":"Blood."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2499-511","DOI":"10.1056\/NEJMoa1505949","article-title":"Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.","volume":"373","author":"M Schaapveld","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1453-62","DOI":"10.1016\/S1470-2045(16)30093-6","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.","volume":"17","author":"S Kreissl","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1325-34","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.","volume":"17","author":"N Bhakta","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"308-16","DOI":"10.1097\/CCO.0000000000000464","article-title":"Hodgkin lymphoma in elderly patients.","volume":"30","author":"S Borchmann","year":"2018","journal-title":"Curr Opin Oncol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1522-9","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.","volume":"31","author":"B B\u00f6ll","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"2375-90","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"S Swerdlow","year":"2016","journal-title":"Blood."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"3220-4","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.","volume":"111","author":"R Yamamoto","year":"2008","journal-title":"Blood."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"2690-7","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.","volume":"34","author":"M Roemer","year":"2016","journal-title":"J Clin Oncol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1611-8","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.","volume":"18","author":"M Green","year":"2012","journal-title":"Clin Cancer Res."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1061-72","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.","volume":"125","author":"J Reichel","year":"2015","journal-title":"Blood."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1715-22","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.","volume":"40","author":"S Muenst","year":"2009","journal-title":"Hum Pathol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1809-19","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL.","volume":"131","author":"F Vari","year":"2018","journal-title":"Blood."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"875-85","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.","volume":"362","author":"C Steidl","year":"2010","journal-title":"N Engl J Med."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"825-36","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.","volume":"132","author":"F Cader","year":"2018","journal-title":"Blood."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"e55-65","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: A technical proof-of-principle study.","volume":"2","author":"P Vandenberghe","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"3070-6","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.","volume":"24","author":"B Klimm","year":"2013","journal-title":"Ann Oncol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"3495-502","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.","volume":"25","author":"A Engert","year":"2007","journal-title":"J Clin Oncol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"3128-35","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.","volume":"24","author":"E Noordijk","year":"2006","journal-title":"J Clin Oncol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"640-52","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.","volume":"363","author":"A Engert","year":"2010","journal-title":"N Engl J Med."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"854-62","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).","volume":"89","author":"L Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"3065-9","DOI":"10.1093\/annonc\/mdt389","article-title":"An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.","volume":"24","author":"A Hay","year":"2013","journal-title":"Ann Oncol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"625-33","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base.","volume":"33","author":"A Olszewski","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-35","first-page":"547","article-title":"Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial.","volume":"120","author":"J Radford","year":"2012"},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1786-94","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial.","volume":"35","author":"M Andr\u00e9","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"943-52","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.","volume":"14","author":"N Skoetz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"2419-29","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.","volume":"374","author":"P Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-39","first-page":"214504","article-title":"FINAL ANALYSIS OF THE AHL2011 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA.","author":"O Casasnovas","year":"2018","journal-title":"EHA Learning Center."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1562-6","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.","volume":"128","author":"R Chen","year":"2016","journal-title":"Blood."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/HS9.0000000000000052","article-title":"The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered.","volume":"2","author":"P Borchmann","year":"2018","journal-title":"HemaSphere."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"339-40","DOI":"10.1182\/blood-2018-04-845438","article-title":"Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven.","volume":"132","author":"H Adams","year":"2018","journal-title":"Blood."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1200\/JCO.2016.34.15_suppl.7508","article-title":"A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.","volume":"34","author":"S Park","year":"2016","journal-title":"JCO."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"JCO2018790139","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.","volume":"36","author":"A Evens","year":"2018","journal-title":"J Clin Oncol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"942-50","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.","volume":"36","author":"M Roemer","year":"2018","journal-title":"J Clin Oncol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1183-94","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.","volume":"131","author":"A Herrera","year":"2018","journal-title":"Blood."},{"key":"ref-47","article-title":"CHECKMATE 205 COHORT D: A PHASE 2 TRIAL OF NIVOLUMAB FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA.","volume":"214507","author":"R Ramchandren","year":"2018"},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"456-60","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.","volume":"31","author":"A Moskowitz","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"480-2","DOI":"10.1111\/j.1365-2141.2009.07963.x","article-title":"Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.","volume":"148","author":"B B\u00f6ll","year":"2010","journal-title":"Br J Haematol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"2197-203","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.","volume":"30","author":"A Younes","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1057-63","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma.","volume":"28","author":"A Gopal","year":"2017","journal-title":"Ann Oncol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1222-8","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.","volume":"12","author":"A Younes","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref-53","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood.V128.22.3502.3502","article-title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed\/Refractory Hodgkin Lymphoma.","volume":"128","author":"P Armand","year":"2016","journal-title":"Blood."},{"key":"ref-54","first-page":"214889","article-title":"ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT IN RELAPSED\/REFRACTORY HODGKIN LYMPHOMA.","author":"J Mear","year":"2018"},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"3462-71","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.","volume":"127","author":"C Ramos","year":"2017","journal-title":"J Clin Invest."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"1156-66","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.","volume":"23","author":"C Wang","year":"2017","journal-title":"Clin Cancer Res."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"798-808","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.","volume":"32","author":"C Bollard","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-58","doi-asserted-by":"crossref","first-page":"653-653","DOI":"10.1182\/blood.V130.Suppl_1.653.653","article-title":"Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory\/Relapsed Hodgkin Lymphoma (HL).","volume":"130","author":"J Svoboda","year":"2017","journal-title":"Blood."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1154-67","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.","volume":"7","author":"M Ruella","year":"2017","journal-title":"Cancer Discov."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"1444-50","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.","volume":"35","author":"P Br\u00f6ckelmann","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1680-7","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.","volume":"18","author":"D Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"570-6","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma.","volume":"48","author":"A Kolstad","year":"2007","journal-title":"Leuk Lymphoma."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T22:17:12Z","timestamp":1662416232000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":62,"URL":"https:\/\/doi.org\/10.12688\/f1000research.16077.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.17557.r40433","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17557.r40432","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.17557.r40433, Zs\u00f3fia Milt\u00e9nyi, Institution of Internal Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary, 13 Nov 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1#referee-response-40433","order":0,"name":"referee-response-40433","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17557.r40432, Stephen Ansell, Department of Hematology, Mayo Clinic in Rochester, Rochester, USA, 13 Nov 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1786\/v1#referee-response-40432","order":1,"name":"referee-response-40432","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}